Literature DB >> 15951931

Clinicopathological factors predicting long-term overall survival after hepatectomy for peripheral cholangiocarcinoma.

Yi-Yin Jan1, Chun-Nan Yeh, Ta-Sen Yeh, Tsann-Long Hwang, Miin-Fu Chen.   

Abstract

Peripheral cholangiocarcinoma (PCC) is clinically challenging because patients typically do not present until the disease is relatively advanced. Three-year to 5-year survival rates even with resection thus remain dismal. This study aimed to determine the clinicopathological factors for predicting overall survival longer than 5 years in PCC patients treated with hepatectomy. From 1977 to 1997, the clinicopatholgical features of 11 PCC patients who underwent hepatectomy with long-term overall survival (group A) were reviewed. Comparison was made with the clinical features and factors influencing the outcome of 70 PCC patients who survived less than 5 years after hepatectomy (group B). Of 81 PCC patients undergoing hepatectomy, 11 (13.6%) were 5-year survivors. The 81 PCC patients comprised 32 men and 49 women, with a mean age of 56.0 years (range: 34-83 years). Univariate analysis showed that female gender, absence of physical findings, a higher percentage of presence of mucobilia, early staged tumor, intraductal papillary tumor growth, and curative hepatic resection were more frequent in group A patients than group B patients. However, multivariate logistic regression analysis showed that absence of physical findings, presence of mucobilia, early staged tumor, and curative hepatic resection were the four independent factors differentiating group A from B patients. The 1-, 3-, 5-, and 10-year survival rates of the group A patients were 100%, 100%, 100%, and 40%, whereas those of the group B patients were 46.0%, 9.5%, 0%, and 0%, respectively. Absence of physical findings, presence of mucobilia, early staged tumor, and curative hepatectomy could independently predict PCC patients with long-term overall survival after hepatectomy.

Entities:  

Mesh:

Year:  2005        PMID: 15951931     DOI: 10.1007/s00268-005-7763-7

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  30 in total

1.  Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.

Authors:  W R Jarnagin; Y Fong; R P DeMatteo; M Gonen; E C Burke; J Bodniewicz BS; M Youssef BA; D Klimstra; L H Blumgart
Journal:  Ann Surg       Date:  2001-10       Impact factor: 12.969

2.  Comparative clinicopathological study of resected intrahepatic cholangiocarcinoma in northeast Thailand and Japan.

Authors:  H Suzuki; S Isaji; C Pairojkul; T Uttaravichien
Journal:  J Hepatobiliary Pancreat Surg       Date:  2000

Review 3.  Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment.

Authors:  M F Chen
Journal:  J Gastroenterol Hepatol       Date:  1999-12       Impact factor: 4.029

Review 4.  Primary sclerosing cholangitis: a clinical review.

Authors:  C I Ponsioen; G N Tytgat
Journal:  Am J Gastroenterol       Date:  1998-04       Impact factor: 10.864

5.  A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables.

Authors:  T Okabayashi; J Yamamoto; T Kosuge; K Shimada; S Yamasaki; T Takayama; M Makuuchi
Journal:  Cancer       Date:  2001-11-01       Impact factor: 6.860

Review 6.  Prevention of bile duct cancer in primary sclerosing cholangitis.

Authors:  P M Harrison
Journal:  Ann Oncol       Date:  1999       Impact factor: 32.976

7.  Predictive factors for long-term survival in patients with intrahepatic cholangiocarcinoma.

Authors:  T Isa; T Kusano; H Shimoji; Y Takeshima; Y Muto; M Furukawa
Journal:  Am J Surg       Date:  2001-06       Impact factor: 2.565

8.  Clinical studies of mucin-producing cholangiocellular carcinoma: a study of 22 histopathology-proven cases.

Authors:  M F Chen; Y Y Jan; T C Chen
Journal:  Ann Surg       Date:  1998-01       Impact factor: 12.969

9.  Intraductal papillary neoplasia of the liver associated with hepatolithiasis.

Authors:  T C Chen; Y Nakanuma; Y Zen; M F Chen; Y Y Jan; T S Yeh; C T Chiu; T T Kuo; J Kamiya; K Oda; M Hamaguchi; Y Ohno; L L Hsieh; Y Nimura
Journal:  Hepatology       Date:  2001-10       Impact factor: 17.425

10.  Analysis of failure following curative irradiation of gallbladder and extrahepatic bile duct carcinoma.

Authors:  S J Buskirk; L L Gunderson; M A Adson; A Martinez; G R May; D C McIlrath; D M Nagorney; G K Edmundson; C E Bender; J K Martin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-11       Impact factor: 7.038

View more
  13 in total

Review 1.  Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.

Authors:  Murad Aljiffry; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

2.  Percutaneous ultrasound-guided thermal ablation for intrahepatic cholangiocarcinoma.

Authors:  H-X Xu; Y Wang; M-D Lu; L-N Liu
Journal:  Br J Radiol       Date:  2012-02-28       Impact factor: 3.039

3.  Clinical parameters predicting survival duration after hepatectomy for intrahepatic cholangiocarcinoma.

Authors:  Bei-ge Jiang; Rui-liang Ge; Liang-liang Sun; Ming Zong; Gong-tian Wei; Yong-jie Zhang
Journal:  Can J Gastroenterol       Date:  2011-11       Impact factor: 3.522

4.  Hepatitis B virus infection: a favorable prognostic factor for intrahepatic cholangiocarcinoma after resection.

Authors:  Hua-Bang Zhou; Hui Wang; Yu-Qiong Li; Shuang-Xi Li; Hao Wang; Dong-Xun Zhou; Qian-Qian Tu; Qing Wang; Shan-Shan Zou; Meng-Chao Wu; He-Ping Hu
Journal:  World J Gastroenterol       Date:  2011-03-14       Impact factor: 5.742

5.  In vitro and in vivo study of GSK2830371 and RG7388 combination in liver adenocarcinoma.

Authors:  Chiao-En Wu; Chiao-Ping Chen; Yi-Ru Pan; Shih-Ming Jung; John Wen-Cheng Chang; Jen-Shi Chen; Chun-Nan Yeh; John Lunec
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

Review 6.  Precision Medicine in Cholangiocarcinoma: Past, Present, and Future.

Authors:  Chi-Yuan Cheng; Chiao-Ping Chen; Chiao-En Wu
Journal:  Life (Basel)       Date:  2022-06-02

7.  Surgery for extrahepatic cholangiocarcinoma: predictors of survival.

Authors:  J J Kloek; F J Ten Kate; O R C Busch; D J Gouma; T M van Gulik
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

Review 8.  Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management.

Authors:  Kelly J Lafaro; David Cosgrove; Jean-Francois H Geschwind; Ihab Kamel; Joseph M Herman; Timothy M Pawlik
Journal:  Gastroenterol Res Pract       Date:  2015-05-19       Impact factor: 2.260

9.  Clinical effect of a positive surgical margin after hepatectomy on survival of patients with intrahepatic cholangiocarcinoma.

Authors:  Chun-Nan Yeh; Feng-Jen Hsieh; Kun-Chun Chiang; Jen-Shi Chen; Ta-Sen Yeh; Yi-Yin Jan; Miin-Fu Chen
Journal:  Drug Des Devel Ther       Date:  2014-12-17       Impact factor: 4.162

10.  Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial.

Authors:  Roman Kloeckner; Christian Ruckes; Kai Kronfeld; Marcus Alexander Wörns; Arndt Weinmann; Peter Robert Galle; Hauke Lang; Gerd Otto; Waltraud Eichhorn; Mathias Schreckenberger; Christoph Dueber; Michael Bernhard Pitton
Journal:  Trials       Date:  2014-08-06       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.